Targets › PV3
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on PV3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PATH | Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3) Live attenuated Type 3 oral poliovirus vaccine | PV3 | Phase 2 | Poliomyelitis | Mar 2027 |
Poliomyelitis (1)
other (1)
PATH (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.